Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 2680 Phase 3 in Narcolepsy Type 2 (Japan)
jRCT2031260309Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of alixorexton in narcolepsy type 2 (NT2) (4 arms), sponsored by Alkermes. Primary endpoint: Change in mean sleep latency on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level. Started Jul 2026; status: recruiting.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on jRCT2031260309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260309.